Last deal

$11M

Amount

Series C

Stage

25.04.2019

Date

7

all rounds

$84.1M

Total amount

General

About Company
Symic Biomedical develops therapeutics to inhibit inflammatory responses in fibrosis, oncology, and CNS.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2012

Number of employees

Company Type

For Profit

Last funding type

Series C

IPO status

Private

Description

Symic Biomedical is a healthcare company that specializes in biotechnology. The company focuses on developing matrix regulator therapeutics that target damaged areas of the matrix, inhibiting pathological inflammatory responses. These therapeutics have applications in the areas of fibrosis, oncology, and diseases of the central nervous system. By binding to damaged targets, Symic Biomedical's therapeutics promote healing and prevent further damage.
Contacts

Phone number

Social url